Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

54.35USD
24 Nov 2017
Change (% chg)

$-0.02 (-0.04%)
Prev Close
$54.37
Open
$54.60
Day's High
$54.60
Day's Low
$54.12
Volume
1,053,381
Avg. Vol
2,998,509
52-wk High
$66.80
52-wk Low
$53.63

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $176,050.70
Shares Outstanding(Mil.): 2,727.35
Dividend: 0.47
Yield (%): 2.91

Financials

  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

BRIEF-Cue Biopharma announces collaboration with Merck

* ‍Cue Biopharma says a strategic research collaboration and license agreement with Merck

16 Nov 2017

BRIEF-Merck reports 6.5 pct passive stake in Spero Therapeutics as of Nov 6

* Merck & Co reports 6.5 percent passive stake in Spero Therapeutics Inc as of Nov 6 - SEC Filing​ Source text: [http://bit.ly/2z57b4q] Further company coverage:

15 Nov 2017

Bayer hires new blood to stem 'Amazon effect' in consumer health

FRANKFURT German drugmaker Bayer has hired the head of Nestle's baby food business to help it reverse a drop in revenue from consumer health brands, which often fail to appeal to buyers on Amazon and other online platforms.

15 Nov 2017

BRIEF-Merck reports final results of any and all tender offers

* Merck & Co Inc - ‍offers expired at 5:00 p.m., New York City time, on Nov. 13, 2017​

14 Nov 2017

BRIEF-Merck announces pricing of any and all tender offers

* Says ‍as of date of offers, aggregate outstanding principal amount of notes was about $2.95 billion​

13 Nov 2017

FDA OKs Merck drug that prevents infection post-stem cell transplant

Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday.

09 Nov 2017

UPDATE 1-FDA OKs Merck drug that prevents infection post-stem cell transplant

Nov 9 Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday.

09 Nov 2017

FDA OKs Merck drug to stop infection post-stem cell transplant

Nov 9 Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday.

09 Nov 2017

BRIEF-Merck receives FDA approval of Prevymis for prevention of CMV infection in allogeneic stem cell transplant patients

* Merck receives FDA approval of Prevymis (letermovir) for prevention of cytomegalovirus (CMV) infection and disease in adult allogeneic stem cell transplant patients

09 Nov 2017

BRIEF-Merck & Co updates on investigation of co's Italian unit

* Merck & Co Inc says in July 2017, co learned that the prosecution office of Milan, Italy is investigating certain interactions - SEC filing

07 Nov 2017

Competitors

Earnings vs. Estimates